Amgen comes up with $1.5B package to partner with CytomX on a preclinical Probody approach to cancer
About six months after Bristol-Myers Squibb forked out $200 million in cash to expand its work with CytomX $CTMX and the precision biology tech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
